Symbols

IDYA

IDEAYA Biosciences·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IDYA

Ideaya Biosciences, Inc.

A company that developing oncology therapies for the treatment of cancer using molecular diagnostics

Industry

Biological Technology

Established Date

Listing Date

05/23/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

145

Fiscal Year Ends

12-31

Website

www.ideayabio.com

Security Type

Common stock

Office address

5000 Shoreline Court, Suite 300, South San Francisco, California 94080

Business

Introduction

IDEAYA Biosciences, Inc., headquartered in South San Francisco, California, was incorporated in Delaware in June 2015. The company is an oncology-focused precision medicine company dedicated to discovering and developing targeted therapies for patient populations selected using molecular diagnostics. Their approach combines the broad ability to identify and validate translated biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies they are developing. They are applying these capabilities to a variety of precision medicine, including direct targeting of carcinogenic pathways and synthetic lethality, which represents an emerging class of precision medicine targets.

Company Financials

EPS

IDYA has released its 2025 Q4 earnings. EPS was reported at -0.94, versus the expected -0.94, meeting expectations. The chart below visualizes how IDYA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IDYA has released its 2025 Q4 earnings report, with revenue of 10.88M, reflecting a YoY change of 55.37%, and net profit of -83.27M, showing a YoY change of 36.10%. The Sankey diagram below clearly presents IDYA's revenue sources and cost distribution.